Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today! OSLO, NORWAY--(Marketwired - August 19, 2013) - Algeta ASA (OSE: ALGETA), a company focused on the ...
German pharmaceutical group Bayer offered to buy Norway's Algeta, its partner for a new prostate cancer treatment, for $2.4 billion, a 27 percent premium to the stock's last close, Algeta said on ...
Add Yahoo as a preferred source to see more of our stories on Google. BERLIN (AP) -- Germany's Bayer AG is set to acquire cancer drug maker Algeta ASA after raising its offer for the Norwegian-based ...
It’s going to cost an extra half-a-billion dollars, but German drug giant Bayer AG (BAYRY) said Thursday that has reached an agreement to acquire its Norwegian-based partner Algeta for $2.9 billion.
The logo of Germany's largest drugmaker Bayer HealthCare Pharmaceuticals is pictured on the front of its building in Berlin April 28, 2011. REUTERS/Fabrizio Bensch FRANKFURT/OSLO (Reuters) - Bayer ...
Algeta and Ablynx enter into a research collaboration to evaluate the potential of novel alpha-pharmaceuticals comprising thorium-227 conjugated to tumor-targeting Nanobodies® Oslo, Norway, and Ghent, ...
Algeta ASA and Ablynx have announced a research collaboration to evaluate a novel Targeted Thorium Conjugate (TTC) based on combining Algeta’s proprietary thorium-227 alpha-pharmaceutical payload with ...
Presentations, where applicable, will be available to download at www.algeta.com following these events. About Algeta Algeta is a company focused on developing novel targeted therapies for patients ...
Oslo, Norway, 4 June 2012 - Algeta ASA (OSE: ALGETA) announces that updated data from the pivotal phase III ALSYMPCA trial for its investigational drug Alpharadin (radium-223 dichloride[1] (#ftn1)) ...
Shares in Algeta, the Norwegian pharmaceutical company that specialises in cancer medicine, are up more than 30 per cent this morning after it confirmed in a statement to the Oslo stock exchange that ...
Oslo, Norway, 19th August 2013 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, is pleased to announce the appointment of Dr Andreas Menrad as ...
FRANKFURT/OSLO (Reuters) - Bayer has won backing from the board of Algeta , its partner for a new prostate cancer treatment, for an increased $2.9 billion offer to buy the Norwegian company. The cash ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results